Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Healthy Male Volunteer
Interventions: JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Adults, Healthy
Interventions: PF-08049820, Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hormone Deficiency, Aging
Interventions: Growth Hormone Releasing Hormone (GHRH ); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Focus of Study Pain Knowledge
Interventions: Pain education; Other
Lead sponsor: Belmont University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Submental Fat
Interventions: RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Constipation
Interventions: Not listed
Lead sponsor: Synergy Health Solutions; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Brooksville, Florida • Casselberry, Florida • Melbourne, Florida

Conditions: Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor
Interventions: ONC206; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure, Sleep Disorders
Interventions: melatonin, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: TAK-954, Itraconazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2); Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Parkinson Disease (PD)
Interventions: Overactive bladder antimuscarinic deprescribing; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chemotherapy-induced Cognitive Impairment
Interventions: Neurocognitive assessments; Behavioral
Lead sponsor: Rachel Miller; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Transgender Persons
Interventions: Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Heart Failure, CAD - Coronary Artery Disease, Stroke Risk, Cardiac Arrythmias, Genetics Hypertension, Genetics, Pharmacogenomics, Pharmacogenomic Testing for Medication Management, Cancer Genetics
Interventions: Color Genomics Genetic Testing Panels; Genetic
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Other Disorders of Vestibular Function, Bilateral, Bilateral Vestibular Deficiency (BVD), Gentamicin Ototoxicity, Labyrinth Diseases, Vestibular Diseases, Sensation Disorders
Interventions: Labyrinth Devices MVI™ Multichannel Vestibular Implant; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: 68Ga-Galmydar, PET/MRI, 18F-FDG; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
Interventions: TIMELY REHAB; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 3
States / cities: Durham, North Carolina • Portland, Oregon • Madison, Wisconsin

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Jose, California + 10 more

Conditions: Alcohol Dependence
Interventions: GSK561679, Placebo; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Effects of Chemotherapy, Cognitive Impairment
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Rosuvastatin, Rosuvastatin plus rifampin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

Contemporary Pain Science Education and Physician Assistant Students

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

Surveying The Outcomes Of Lubiprostone (The STOOL Study) in Nursing Home Residents

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Melatonin Supplementation to Improve Sleep in Patients With Heart Failure

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

Electrophysiological Effects of Potential QT Prolonging Drugs

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

Effect of Testosterone Treatment on Drug Metabolism and Transport

The Effect of Providing Genetic Risk Information on Lifestyle Behaviors in African Americans

Multichannel Vestibular Implant Early Feasibility Study

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

Maximizing Quality of Life After Cancer Through Rehabilitation

Effect of Interleukin-2 on HIV Treatment Interruption

CRF1 Antagonist GSK561679 in Alcoholism

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

Cognitive Changes in Adult Cancer Survivors

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin